TASS, February 19. The American company Johnson & Johnson has filed an application with the World Health Organization (WHO) for emergency use of the coronavirus vaccine of its Janssen division. This was announced in a statement published on Friday on the company's website.
"Johnson & Johnson announced that Janssen Cilag International has applied to WHO to be listed as an emergency drug for Janssen, an experimental single-dose COVID-19 vaccine," the statement said.
It is noted that the company has submitted a package of documents to the organization, which includes preliminary assessments of the safety and efficacy of the vaccine based on data obtained during the third phase of clinical trials.
According to Johnson & Johnson in late January, the drug has shown up to 85% efficacy in a third phase of trials in the United States and beyond.
On February 15, WHO approved two variants of the coronavirus vaccine from the British-Swedish company AstraZenec and the University of Oxford for emergency use. Earlier, the organization received the approval of the Comirnaty vaccine, developed jointly by Pfizer from the USA and BioNTech from Germany.
As explained in the WHO, the approval procedure provides for an assessment of the "safety and efficacy of vaccines against COVID-19." Only after the completion of this procedure, the drugs can be supplied to the countries of the world through the international mechanism for accessing COVAX vaccines. In addition, listing by WHO "enables countries to expedite their own regulatory approval for the import and use of vaccines."